Robert J. Beall, has been with the Cystic Fibrosis (CF) Foundation for more than 30 years and currently serves as president and CEO. Beall began his tenure as executive vice president for medical affairs, and for the past 18 years, he has served as president and CEO. Prior to joining the CF Foundation, Beall was on the medical school faculty of Case Western Reserve University in Cleveland, Ohio, and at NIH, where he managed a large portion of the agency’s cystic fibrosis program.
Under Beall’s leadership, the CF Foundation has become one of the most respected voluntary health organizations in the country and is recognized for its innovative approaches to bringing new therapies to patients with the disease. The creation of an innovative research centers program in the 1980s (the Research Development Program) attracted many leading institutions and first-rate scientists to the CF research effort. This collaborative network contributed to the identification of the CF gene in 1989. Since that time, the focus has been on translating knowledge about the gene and the basic defect into the development of novel CF treatments.
In 1998, the CF Foundation launched its ground-breaking Therapeutics Development Program, a unique coalition between industry, academia and the CF Foundation that is directed at the discovery and development of additional approaches to CF drug discovery and development. As a result of the pioneering business model of the CF Foundation, there are currently nearly 30 potential CF therapeutic products in the development pipeline, and the prospects for a cure and control for cystic fibrosis have never been higher.
Beall received his doctorate in biochemistry from the State University of New York at Buffalo.